Verve Therapeutics, Inc. (VERV): Price and Financial Metrics
GET POWR RATINGS... FREE!
VERV Stock Price Chart Interactive Chart >
VERV Price/Volume Stats
|Current price||$22.57||52-week high||$43.00|
|Prev. close||$23.29||52-week low||$10.70|
|Day high||$22.99||Avg. volume||598,479|
|50-day MA||$21.28||Dividend yield||N/A|
|200-day MA||$24.68||Market Cap||1.39B|
Verve Therapeutics, Inc. (VERV) Company Bio
Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease.
Most Popular Stories View All
VERV Latest News Stream
|Loading, please wait...|
VERV Latest Social Stream
View Full VERV Social Stream
Latest VERV News From Around the Web
Below are the latest news stories about VERVE THERAPEUTICS INC that investors may wish to consider to help them evaluate VERV as an investment opportunity.
The tech-heavy Nasdaq represents a collection of more risky stocks than the other major indexes and that is reflected by a poorer performance in bear markets and a better display during bull runs. But the risks associated with the Nasdaq are mere child play compared to edgier funds such as Cathie Wood’s Ark Innovation ETF. Now that really hit the skids during last year’s bear, but the fund is also up 37% year-to-date, putting the Nasdaq's 15% gain in the shade. In fact, throwing more shade the N
Cantor Fitzgerald initiated coverage on Verve Therapeutics Inc (NASDAQ: VERV) with a Neutral rating and a price target of $21. The analyst says Verve is a true pioneer in gene editing, planning to develop base editing medicines for HeFH and the prevention of ASCVD, both prevalent diseases with large potential markets. However, the analyst sees heightened regulatory and commercial risk compared to other gene-editing/ genetic medicines companies focused on rare diseases. The analyst believes it wo
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 4:30 p.m. PT in San Francisco. A live webcast will be available in the investor section of the company's websit
VERV Price Returns